{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:45:01Z","timestamp":1793191501270,"version":"4.5.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Objective: To review the microbiological activity, safety, and efficacy of the new fluoroquinolone delafloxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Data Sources: A PubMed search from 1945 to September 2018 was done using the terms delafloxacin, acute bacterial skin and skin structure infections, skin and soft tissue infections, and fluoroquinolone. Additional sources include the Food and Drug Administration website, ClinicalTrials.gov, and the Melinta Therapeutics website. Study Selection and Data Extraction: The literature search was limited to those published in the English language and included in vitro and human studies that evaluated microbiological coverage, pharmacokinetics, pharmacodynamics, safety, and\/or efficacy. Data Synthesis: Delafloxacin is a new fluoroquinolone with a unique structure for its class that covers both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas. This new antibiotic has demonstrated noninferiority to vancomycin plus aztreonam for the treatment of ABSSSIs in both an intravenous-only regimen and an intravenous to an oral regimen. Relevance to Patient Care and Clinical Practice: ABSSSIs are infections that are most often caused by Staphylococcus and represent one of the most common types of hospital infections. MRSA represents about half of all staphylococcal skin infections, and along with gram-negative infections, increase the rates of patient morbidity and health care costs. Delafloxacin is an additional treatment option that covers both of these types of microorganisms. Conclusions: Delafloxacin is a safe and effective treatment option for ABSSSIs, particularly in those with polymicrobial infections and those with MRSA.<\/jats:p>","DOI":"10.1177\/8755122519834615","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T03:08:52Z","timestamp":1552273732000},"page":"110-118","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-2125","authenticated-orcid":false,"given":"Young Ran","family":"Lee","sequence":"first","affiliation":[{"name":"Texas Tech University Health Sciences Center, Abilene, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin Elizabeth","family":"Burton","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Sciences Center, Abilene, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kolton Rucks","family":"Bevel","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Sciences Center, Abilene, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"bibr1-8755122519834615","unstructured":"US Food and Drug Administration. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071185.pdf. Published October 2013. Accessed September 18, 2018."},{"key":"bibr2-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1016\/S1198-743X(16)30095-7"},{"key":"bibr3-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2014.12.001"},{"key":"bibr4-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1071-0"},{"key":"bibr5-8755122519834615","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.39"},{"key":"bibr6-8755122519834615","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S106071"},{"key":"bibr7-8755122519834615","unstructured":"Baxdela\u00ae [package insert]. Lincolnshire, IL: Melinta Therapeutics, Inc; 2017."},{"key":"bibr8-8755122519834615","unstructured":"Cipro\u00ae [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc; 2009."},{"key":"bibr9-8755122519834615","unstructured":"Levaquin\u00ae [package insert]. Raritan, NJ: Ortho-McNeil-Jannsen Pharmaceuticals, Inc; 2008."},{"key":"bibr10-8755122519834615","unstructured":"US Committee on Antimicrobial Susceptibility Testing (USCAST). MIC breakpoint tables comparing the interpretive criteria of CLSI, EUCAST, USA-FDA and USCAST. http:\/\/www.uscast.org\/uploads\/2\/5\/7\/4\/25741546\/comparison_tables_for_website_-__june_2015.pdf. Published June 23, 2015. Accessed November 28, 2018."},{"key":"bibr11-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02609-16"},{"key":"bibr12-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2003.00696.x"},{"key":"bibr13-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.817"},{"key":"bibr14-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.10.016"},{"key":"bibr15-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0198-x"},{"key":"bibr16-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0520-8"},{"key":"bibr17-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy220"},{"key":"bibr18-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04813-14"},{"key":"bibr19-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1039\/c8pp00019k"},{"key":"bibr20-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv411"},{"key":"bibr21-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.10.009"},{"key":"bibr22-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx329"},{"key":"bibr23-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1177\/193229681000400405"},{"key":"bibr24-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy165"},{"key":"bibr25-8755122519834615","unstructured":"Melinta Therapeutics. Melinta Therapeutics initiates phase 3 study of Baxdela in hospital-treated community acquired bacterial pneumonia. http:\/\/melinta.com\/melinta-therapeutics-initiates-phase-3-study-of-baxdela-in-hospital-treated-community-acquired-bacterial-pneumonia\/. Published January 6, 2016. Accessed September 18, 2018."},{"key":"bibr26-8755122519834615","unstructured":"ClinicalTrials.gov. Study to compare delafloxacin to moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02679573. Published February 10, 2016. Accessed September 18, 2018."},{"key":"bibr27-8755122519834615","unstructured":"Melinta Therapeutics. Melinta Therapeutics ceases phase 3 proceeding study. http:\/\/melinta.com\/melinta-therapeutics-ceases-phase-3-proceeding-study\/. Accessed September 18, 2018."},{"key":"bibr28-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02798-15"},{"key":"bibr29-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu444"},{"key":"bibr30-8755122519834615","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"bibr31-8755122519834615","unstructured":"IBM Micromedex RED BOOK. Micromedex Healthcare Series [database online]. Greenwood Village, CO: Truven Health Analytics; 2015."}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/8755122519834615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/8755122519834615","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/8755122519834615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:28:47Z","timestamp":1777602527000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/8755122519834615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1177\/8755122519834615"],"URL":"https:\/\/doi.org\/10.1177\/8755122519834615","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]}}}